Loading...
You are here:  Home  >  News  >  Business  >  Current Article

Datopotamab Deruxtecan Shows Encouraging Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Genomic Alterations

By   /  September 20, 2021  /  Comments Off on Datopotamab Deruxtecan Shows Encouraging Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Genomic Alterations

    Print       Email


TOKYO & MUNICH & BASKING RIDGE, N.J.–()–New data for datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC) being developed by Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca, show an encouraging tumor response rate in patients with advanced non-small cell lung cancer (NSCLC) with actionable genomic alterations. A sub-analysis of the NSCLC cohort of the TROPION-PanTumor01 phase 1 trial was presented as a late-breaking Mini Oral presentation (#LBA49) at the European Society for Medical Oncology (#ESMO21) 2021 Virtual Congress.

Lung cancer is the second most common cancer and the leading cause of cancer-related mortality worldwide, with 80 to 85%…



Click here to view the original article.

    Print       Email

You might also like...

Recession warning: BoE official predicts 2008-level economic crash due to Bitcoin & crypto

Read More →